top of page
Home: Welcome
My view on what's going on in the financial markets and the global economy, and a few other things that might interest me from time to time.
Search
tim@emorningcoffee.com
22 minutes ago5 min read
Week ended Jan 10, 2025: markets under pressure
Stock and bond markets felt fragile all week. The US Dec jobs report caused investments to gap down in price to end a difficult week.
20
tim@emorningcoffee.com
3 days ago13 min read
American Exceptionalism
Better late than never, in that this article is about my views on American exceptionalism, both economically and as far as US stocks.
280
tim@emorningcoffee.com
6 days ago2 min read
Week ended Jan 3, 2025
We start 2025 with a mixed picture, not surprising in that the new year consisted of a holiday week. Friday was better in US stocks.
210
tim@emorningcoffee.com
Jan 31 min read
Summary of 2024 in tables
This article contains a summary of full-year 2024 performance of the indices and assets tracked by EMC, plus historical data, too.
470
tim@emorningcoffee.com
Dec 31, 20248 min read
2024 market and asset performance vs my expectations: how'd I do?
I "guessed" at how markets would perform in 2024 last year at this time. Some I got right, some I got wrong, not different from the pros.
390
tim@emorningcoffee.com
Nov 27, 202411 min read
A quick look at MicroStrategy (MSTR)
MicroStrategy (MSTR) has had an amazing run since it adopted its Bitcoin accumulation strategy in Aug 2020. Has it run too far too fast?
770
tim@emorningcoffee.com
Nov 12, 20245 min read
Does the "Trump rally" have legs?
Some stocks that clearly "track" President-elect Trump's varied campaign promises have rallied hard, including TSLA, BTC, COIN and KRE.
241
tim@emorningcoffee.com
Nov 7, 20243 min read
The US election aftermath: the morning after
This article is short and covers the blowout results and reasons, what Trump 2.0 means for investors, and Mr Trump's promises.
130
tim@emorningcoffee.com
Nov 3, 20244 min read
The US election: things you should know
Here are a few last-minute thoughts on the US election which will be held on Tuesday, Nov 5. A lot is at stake, but Weds, the world goes on
500
tim@emorningcoffee.com
Oct 9, 20249 min read
Portfolio update: 3Q2024
This is the update of my personal portfolio for the most recent quarter ended September 30, 2024.Â
890
tim@emorningcoffee.com
Sep 25, 202410 min read
Three key election issues: immigration, inflation and abortion
There are many important issues in the US Presidential election, but none more so perhaps than immigration, inflation, and abortion.
820
tim@emorningcoffee.com
Jul 24, 20248 min read
Portfolio update: 1H2024
This is an update of my personal portfolio performance in 2Q2024 and 1H2024, good on the surface but worse than the indices would suggest.
750
tim@emorningcoffee.com
Jun 25, 20246 min read
US deficits / debt soar; should you care?
US deficits are soaring, along with US debt to finance the "exceptional growth" of the US. Can this continue?
890
tim@emorningcoffee.com
Jun 12, 20247 min read
Midweek update: Apple, CPI/FOMC, GME
We have some US data coming that might matter today (CPI), but the FOMC will sit tight (also today). Discusses Apple's run and GameStop.
240
tim@emorningcoffee.com
May 2, 202414 min read
Is fine wine a good investment?
The 2024 en primeur campaign for Bordeaux is just starting. But is fine wine really a good investment? I don't think so anymore.
4094
tim@emorningcoffee.com
Apr 10, 20248 min read
Portfolio update: 1Q2024
This is an update about my personal portfolio during and at the end of 1Q2024. It also discusses performance which I consider disappointing.
740
tim@emorningcoffee.com
Mar 18, 20248 min read
Anti-obesity medications: part 3, valuations of LLY and NVO
This is the 3rd and final article focused on anti-obesity drugs. It looks at valuations of shares of the two giants in this biz, LLY & NVO.
550
tim@emorningcoffee.com
Mar 14, 20247 min read
Anti-obesity medications part 2: the duopoly of Eli Lilly and Novo Nordisk
Eli Lilly (LLY) and Novo Nordisk (NVO) have been large players for decades in the market for diabetes medications and are currently...
500
Home: Blog2
bottom of page